Panel Discussion: Evaluating the Cutting-Edge Innovation & Performance Driving ADC Differentiation & Progression Earlier Line Patient Therapies
- Understanding the 2026 ADC landscape and how the bar has been raised to develop and deliver differentiated ADCs with meaningful patient impact
- Assessing the need for novel ADC chemistry innovation: What is showing the most promise across novel payloads and conjugation technologies?
- Discussing the potential of novel ADC biology approaches across bispecific targeting and antibody engineering to unlock next generation ADC therapies
- Highlighting methods to best pursue ADC clinical differentiation across patient selections methods, combination strategies, and well executed clinical design